Immunotherapy Regimens in dMMR/MSI-High Metastatic CRC

Remaining questions for the treatment of patients with MSI/dMMR mCRC with immunotherapyПодробнее

Immunotherapy in CRC | 2023 Best of GI Cancer ConferenceПодробнее

Neoadjuvant immunotherapy in MSI-high colorectal cancerПодробнее

Analysis of HLA gene expression in dMMR/MSI-H, ICI-resistant CRCПодробнее

KEYNOTE-177 & CheckMate 142: checkpoint blockade in MSI-H/dMMR CRCПодробнее

Significance of MSI Status and TMB in Metastatic CRCПодробнее

Current and future trends in immunotherapy for MSI-H colorectal cancerПодробнее

Debate: MSI High Colon Cancer - ImmunotherapyПодробнее

Immunotherapy for MSI High Colon CancerПодробнее

Immunotherapy in MSI-H/dMMR mCRC: first-line options and dual checkpoint inhibition insightsПодробнее

CheckMate-8HW: nivolumab and ipilimumab in MSI-H/dMMR mCRCПодробнее

Dr. Chu on the Role of Pembrolizumab in dMMR/MSI-H mCRCПодробнее

What's New in Colorectal Cancer Treatment? by Michael Hall, MD, MSПодробнее

Dr. Nelson on the CheckMate-142 Trial in MSI-H/dMMR mCRCПодробнее

Interdisciplinary Approaches to Personalizing Immunotherapy in Metastatic CRCПодробнее

Other I-O Approaches to Metastatic Colorectal CancerПодробнее

Nivolumab/Ipilimumab Combination Data Promising in MSI-H/dMMR mCRCПодробнее

Expert report on immune checkpoint inhibitors for dMMR Colorectal CancerПодробнее

Immunotherapy in CRCПодробнее